Taysha Gene Therapies: Analysts Bullish on the Stock Amid Progress in Rett Syndrome Trials

Taysha Gene Therapies (TSHA) is a clinical-stage biotech company developing AAV-based gene therapies for CNS monogenic diseases. Analysts are bullish on the stock, maintaining a Buy rating with a $10 price target. The company has reached alignment with the FDA on the inclusion of ≥3 months of safety data from the ASPIRE trial in the planned BLA submission. Dosing in pivotal trials is expected to be completed in Q2 2026, with longer-term safety and efficacy data updates expected in H1 2026.